Evidence map›Paper›PMID 36523295›Full record

ArticleTranslational cancer research2022

Knockdown of Nrf2 radiosensitizes glioma cells by inducing redox stress and apoptosis in hypoxia.

Ting Tang, Yue Jia, Hui Liang, Yanling Han, Zixiang Cong, Handong Wang, Xiangjun Ji

Open access · diamondAbstract read
In one paragraph

Article in Translational cancer research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Ting Tang *Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, China.
Yue Jia *Department of Neurosurgery, Jinling Hospital, Nanjing, China.
Hui LiangDepartment of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Yanling HanDepartment of Neurosurgery, Jinling Hospital, Nanjing, China.
Zixiang CongDepartment of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Handong WangDepartment of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Xiangjun JiDepartment of Neurosurgery, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
Nanjing General Hospital of Nanjing Military Command · CNJinling Institute of Technology · CNNanjing Medical University · CNNanjing University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Radiotherapy remains a mainstream treatment for patients with glioma. Yet intrinsic radioresistance has largely compromised the efficacy of the treatment. Increasing concerns have been raised that overexpression of the Nrf2, along with a hypoxic tumor microenvironment, may have contributed to the deterioration of radiotherapy in tumors. So, this study investigated the role of Nrf2 in the radiation therapy of glioma cells in hypoxia. Methods: To determine the expression levels of Nrf2 and HIF-1α, surgical mastectomy specimens from patients with glioma in our institute were analyzed by immunohistochemical staining. Glioblastoma multiforme (GBM) cell lines U251 and U87 with Nrf2 knocked down were produced by transfection with lentiviral particles. Cell lines were treated with ionizing radiation in hypoxia Results: Nrf2 and its downstream pathway were upregulated in surgical specimens after radiotherapy, verified by GBM cell lines treated with Conclusions: Downregulation of Nrf2 could sensitize the lethal effect on GBM cells

Indexed as

GliomahypoxiaNrf2radiotherapy

Identifiers

PMID36523295
PMCPMC9745379
OpenAlexW4310812554

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.